These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease. Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184 [TBL] [Abstract][Full Text] [Related]
3. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645 [TBL] [Abstract][Full Text] [Related]
4. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537 [TBL] [Abstract][Full Text] [Related]
5. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment]. Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216 [TBL] [Abstract][Full Text] [Related]
6. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420 [TBL] [Abstract][Full Text] [Related]
9. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain. Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686 [TBL] [Abstract][Full Text] [Related]
10. Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study. Chalandon Y; Mamez AC; Giannotti F; Beauverd Y; Dantin C; Mahne E; Mappoura M; Bernard F; de Ramon Ortiz C; Stephan C; Morin S; Ansari M; Simonetta F; Masouridi-Levrat S Transplant Cell Ther; 2022 Nov; 28(11):765.e1-765.e9. PubMed ID: 35953029 [TBL] [Abstract][Full Text] [Related]
11. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome. Agrawal V; Ranganath P; Ervin KD; Schmidt CA; Cox EA; Nelson RP; Schwartz JE; Zaid MA; Abonour R; Robertson MJ; Brinda BJ; Griffin SP; Thakrar TC; Farag SS Bone Marrow Transplant; 2021 Jan; 56(1):121-128. PubMed ID: 32623447 [TBL] [Abstract][Full Text] [Related]
12. Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation. Giglio F; Xue E; Greco R; Lazzari L; Clerici DT; Lorentino F; Mastaglio S; Marktel S; Lupo-Stanghellini MT; Marcatti M; Corti C; Bernardi M; Piemontese S; Ciceri F; Peccatori J Front Oncol; 2022; 12():933317. PubMed ID: 35785209 [TBL] [Abstract][Full Text] [Related]
13. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800 [TBL] [Abstract][Full Text] [Related]
14. Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. Lee J; Yoon JH; Kwag D; Lee JH; Kim TY; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Wook Lee J; Hak Lee S; Lee S Ther Adv Hematol; 2021; 12():20406207211066176. PubMed ID: 34987745 [TBL] [Abstract][Full Text] [Related]
15. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Rubinstein JD; O'Brien MM Front Immunol; 2023; 14():1237738. PubMed ID: 37600823 [TBL] [Abstract][Full Text] [Related]
16. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation. Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411 [TBL] [Abstract][Full Text] [Related]
17. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833 [TBL] [Abstract][Full Text] [Related]
18. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Battipaglia G; Labopin M; Candoni A; Fanin R; El Cheikh J; Blaise D; Michallet M; Ruggeri A; Contentin N; Ribera JM; Stadler M; Sierra J; von dem Borne PA; Bloor A; Socié G; Nagler A; Mohty M Bone Marrow Transplant; 2017 Apr; 52(4):592-599. PubMed ID: 28092357 [TBL] [Abstract][Full Text] [Related]
19. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Metheny LL; Sobecks R; Cho C; Fu P; Margevicius S; Wang J; Ciarrone L; Kopp S; Convents RD; Majhail N; Caimi PF; Otegbeye F; Cooper BW; Gallogly M; Malek E; Tomlinson B; Gerds AT; Hamilton B; Giralt S; Perales MA; de Lima M Blood Adv; 2024 Mar; 8(6):1384-1391. PubMed ID: 38170741 [TBL] [Abstract][Full Text] [Related]
20. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia]. An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520 [No Abstract] [Full Text] [Related] [Next] [New Search]